|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1615 L Street NW |
Address2 | Suite 320 |
City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Washington DC |
State | DC |
Zip Code | 20036 |
Country | USA |
|
5. Senate ID# 4356-12
|
||||||||
|
6. House ID# 336910000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Sydney Young |
Date | 1/17/2024 3:30:39 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
out-of-pocket costs, drug prices, utilization management, prior authorization, step therapy, clinical trial diversity, COVID-19 therapeutics, pharmacist scope of practice, telehealth extensions , association health plans, self-insurance protections, short-term limited duration insurance plans
-HR 830/S 1357,HELP Copays Act
-HR 2630/ S. 652, Safe Step Act
-S 1339, Pharmacy Benefit Manager Reform Act
-HR 1770, the Equitable Community Access to Pharmacist Services Act
-HR 824, the Telehealth Benefit Expansion for Workers Act
-Accelerating Kid's Access to Care Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Hyde |
|
Vice President, Advocacy and Access |
|
Alisa |
Vidulich Casavant |
|
Policy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-HR 830 / S 1357, HELP Copays Act
-HR 2630 / S 652, Safe Step Act
-S 1339, Pharmacy Benefit Manager Reform Act
-H.R. 1770, the Equitable Community Access to Pharmacist Services Act
-HR 824, the Telehealth Benefit Expansion for Workers Act
-Accelerating Kids Access to Care Act
- S. 127 Pharmacy Benefit Manager Transparency Act of 2023
- S. 1339 Pharmacy Benefit Manager Reform Act
- H.R. 4507 Transparency in Coverage Act of 2023
- H.R. 4822 Health Care Price Transparency Act of 2023
- H.R. 3561 PATIENT Act of 2023
-H.R. 5378 - The Lower Costs, More Transparency Act
- H.R. 2761 SPARC Act, Specialty Physicians Advancing Rural Care (SPARC) Act
- S.1701/H.R.3503 NIH Clinical Trial Diversity Act of 2023
- H.R. 1114 Long COVID RECOVERY NOW Act
- S.2840 the Bipartisan Primary Care and Health Workforce Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Hyde |
|
Vice President, Advocacy and Access |
|
Alisa |
Vidulich Casavant |
|
Policy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY24 Appropriations - PSLRP and CDRMP for Arthritis, NIH and CDC, improving osteoporosis care and awareness
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Defense - Dept of (DOD), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Hyde |
|
Vice President, Advocacy and Access |
|
Alisa |
Vidulich Casavant |
|
Policy Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |